Abstract
The pharmacological actions of thymoquinone (TQ) are multi-targeting and involve a numbers of cell signaling pathways such as Akt, IRAK-1/NF-kB, IL-17/TNF-α/IL-6/IL-1β, etc. TQ can thus be used to inhibit some cell signaling pathways, which in turn will affect the secretion of some important biological molecules critical in the pathogenesis of many diseases or ailments. In spite of the numerous beneficial actions of TQ, its therapeutic use is currently limited because of some of its clinically undesirable properties, such as poor solubility and sensitivity. In order to increase its solubility and bioavailability, TQ is being incorporated in drug delivery systems. By virtue of its multi-targeting nature and non-toxicity, TQ appears to be an excellent natural molecule to be used as a therapeutic or adjunct molecule to treat/prevent various diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alam S, Khan ZI, Mustafa G et al (2012) Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomed 7:5705–5718
Ganea GM, Fakayode SO, Losso JN et al (2010) Delivery of phytochemical thymoquinone using molecular micelle modified poly (D, L lactide-co-glycolide) (PLGA) nanoparticles. Nanotechnology 21(28):285104
Hossen MJ, Yang WS, Kim D et al (2017) Thymoquinone: an IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities. Sci Rep 7:42995
Jacot JL, Sherris D (2011) Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy. J Ophthalmol 2011:589813. https://doi.org/10.1155/2011/589813
Jain A, Pooladanda V, Bulbake U et al (2017) Liposphere-mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine 13(7):2251–2262
Khan MA, Shehwaz A, Aljarbou AN, Mohammad A-O, Aldebasi YH, Islam S, Younus H (2014) Protective effect of thymoquinone on glucose or methylglyoxal-induced glycation of superoxide dismutase. Int J Biol Macromol 65:16–20
Kirui PK, Cameron J, Benghuzzi HA et al (2004) Effects of sustained delivery of thymoqiunone on bone healing of male rats. Biomed Sci Instrum 40:111–116
Kuwabara T, Ishikawa F, Kondo M et al (2017) The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm 2017:3908061. https://doi.org/10.1155/2017/3908061
Lan A, Du J (2015) Potential role of Akt signaling in chronic kidney disease. Nephrol Dial Transplant 30(3):385–394
Liu T, Zhang L, Joo D et al (2017) NF-κB signaling in inflammation. Signal Transduct Target Ther 2:17023
Mackenzie RWA, Elliott BT (2014) Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 7:55–64
Martini M, De Santis MC, Braccini L et al (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46(6):372–383
Nair HB, Sung B, Yadav VR et al (2010) Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 80(12):1833–1843
Norwood AA, Tucci M, Benghuzzi H (2007) A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells. Biomed Sci Instrum 43:272–277
Odeh F, Ismail SI, Abu-Dahab R et al (2012) Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv 19:371–377
Rajput S, Puvvada N, Kumar BN et al (2015) Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm 12(12):4214–4225
Richards LR, Jones P, Hughes J et al (2007) LNCaP cells exposed to ceramic drug delivery treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid. Biomed Sci Instrum 43:242–247
Su X, Ren Y, Yu N et al (2016) Thymoquinone inhibits inflammation, neoangiogenesis and vascular remodeling in asthma mice. Int Immunopharmacol 38:70–80
Wang D, Qiao J, Zhao X et al (2015) Thymoquinone inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing NF-κB and MAPKs signaling pathway. Inflammation 38(6):2235–2241
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Younus, H. (2018). Future Prospects and Conclusions. In: Younus, H. (eds) Molecular and Therapeutic actions of Thymoquinone. Springer, Singapore. https://doi.org/10.1007/978-981-10-8800-1_8
Download citation
DOI: https://doi.org/10.1007/978-981-10-8800-1_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-8799-8
Online ISBN: 978-981-10-8800-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)